TX-RIVERSAND/WUNDERMAN
Riversand, a leading cloud-native SaaS Master Data Management (MDM) and Product Information Management (PIM) solution provider, and Wunderman Thompson Commerce, the leading global digital agency in commerce, announced today their alliance to help organizations deliver winning commerce capabilities across all digital touchpoints, including third-party marketplaces such as Amazon, online retail, direct to consumer (D2C) and social media.
This partnership enables Wunderman Thompson Commerce to jointly offer consulting and system integration services with Riversand’s market-leading MDM software. Riversand’s customers will benefit from Wunderman Thompson Commerce’s integrated consulting and implementation skills.
“Collaborating with Riversand offers retailers, CPGs, and healthcare/pharmaceutical companies a forward-thinking and comprehensive cloud-native software, teamed with our proven record in successful implementation delivery,” said Nils Kijkuit, director of Marketing and Sales EMEA at Wunderman Thompson Commerce.
As companies transform their digital strategy and move to the cloud to improve the customer experience, implementing a robust system with quality data is the foundation for all eCommerce strategies. Wunderman Thompson Commerce has invested in building and training a number of business and technology consultants to deliver Riversand’s MDM and PIM software solutions efficiently in DACH, Benelux and the UK.
“Wunderman Thompson Commerce offers deep knowledge of MDM and PIM strategy, solution design, integration and implementation to help businesses improve their customer experience, product data, operational processes and profitability. We look forward to working together to optimize our customers’ eCommerce strategies,” said Ben Rund, vice president of Business Development in Europe at Riversand.
About Wunderman Thompson Commerce
Wunderman Thompson Commerce is a global eCommerce consultancy of 1500+ commerce experts across more than 20 offices, united in helping clients win through eCommerce.
We define and deliver digital growth for ambitious brands, retailers and manufacturers. The cornerstone is inspiration – and we seek and promote it in all that we do.
Our global eCommerce consultancy offers strategic clarity, technology enablement and creative insight and delivers winning commerce capabilities across all major channels: marketplaces (including Amazon), online retailers, D2C and social commerce.
We help brands increase results at scale on Amazon, deliver eCommerce strategy and optimise multichannel journeys. We inspire customer engagement and transactions at every touchpoint, while deploying and integrating world class technology from key strategic partners including Adobe, SAP, Salesforce, HCL and IBM.
Clients include AkzoNobel, DFS, Halfords, Jumbo, RXBAR, Sainsbury’s, Selfridges, Specialized, Tempur and Tiffany & Co.
Follow us on Twitter , Facebook , LinkedIn , and Instagram .
About Riversand
Riversand cloud-native master data management solutions are designed to support customers’ digital transformation journeys through improved business agility, faster adoption and improved collaboration across the enterprise. Riversand has a vision of helping companies know their customers better, move products faster, automate processes, mitigate risk and run their businesses smarter. Visit https://Riversand.com for more information and follow us @RiversandMDM on Twitter and Riversand on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005949/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom